Pfizer ends COVID-19 trial with 95% efficacy

Middle East
18-11-2020 | 12:36
High views
Share
LBCI
Share
LBCI
Whatsapp
facebook
Twitter
Messenger
telegram
telegram
print
Pfizer ends COVID-19 trial with 95% efficacy
Whatsapp
facebook
Twitter
Messenger
telegram
telegram
print
2min
Pfizer ends COVID-19 trial with 95% efficacy
Pfizer Inc said on Wednesday that final results from the late-stage trial of its COVID-19 vaccine showed it was 95% effective, adding it had the required two-months of safety data and would apply for emergency U.S. authorization within days.

The final analysis comes just one week after initial results from the trial showed the vaccine was more than 90% effective. Moderna Inc on Monday released preliminary data for its vaccine, showing similar effectiveness.

MARKET REACTION: Equity markets strengthened slightly on the news. Europe's STOXX 600 and U.S. S&P 500 e-mini futures both hit session highs. However, the moves were small compared to the jump after Pfizer's previous announcement. The reaction in European government bonds and in currencies was muted.

Pfizer shares were 2.6% higher in U.S. morning trade at $36.98 and U.S.-listed shares of partner BioNTech SE were up 3% at $89.61.
 
 
REUTERS

Breaking Headlines

Pfizer

Covid-19

Coronavirus

Vaccine

Download now the LBCI mobile app
To see the latest news, the latest daily programs in Lebanon and the world
Google Play
App Store
We use
cookies
We use cookies to make
your experience on this
website better.
Accept
Learn More